{
  "drug_name": "ertapenem",
  "nbk_id": "NBK599511",
  "url": "https://www.ncbi.nlm.nih.gov/books/NBK599511/",
  "scraped_at": "2026-01-11T15:28:54",
  "sections": {
    "indications": "Moxifloxacin is contraindicated in individuals with known hypersensitivity or allergic reactions to moxifloxacin or other fluoroquinolone antibiotics.\n\nBox Warnings\n\nThe FDA warns of tendon disorders associated with fluoroquinolone use, including tendonitis or rupture. Moxifloxacin is contraindicated for patients with a history of myasthenia gravis due to the risk of exacerbating muscle weakness.\n[29]\nConcerns arise about its safety in individuals younger than 18, as it may potentially impact developing musculoskeletal structures.\n[30]\nFluoroquinolones, including moxifloxacin, increase the risk of sensory or sensorimotor axonal polyneuropathy, leading to paresthesias, hypoesthesias, dysesthesias, and muscle weakness. Neuropathy may manifest soon after administration and can be irreversible. Therefore, prompt cessation of moxifloxacin is required upon the presentation of peripheral neuropathy symptoms, including pain, burning, tingling, numbness, or weakness. Caution should be exercised when administering fluoroquinolones, including moxifloxacin, to patients with a history of peripheral neuropathy.\n[31]\n\nWarnings and Precautions\n\nMoxifloxacin is generally avoided during pregnancy and breastfeeding unless the potential benefits outweigh the risks, as it may adversely affect fetal development and pass into breast milk. Caution is warranted when prescribing moxifloxacin to individuals with a history of epilepsy or other seizure disorders due to its potential to reduce the threshold and increase the risk of seizures.\n[32]\n\nMoxifloxacin can cause QT interval prolongation on an electrocardiogram (ECG), necessitating cautious use in individuals with a history of arrhythmias or those taking medications that also prolong the QT interval. Individuals with severe liver impairment should avoid moxifloxacin or use it cautiously, as it may exacerbate liver dysfunction. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency—a genetic enzyme deficiency—should exercise caution when using moxifloxacin, as it can trigger hemolysis (breakdown of red blood cells) in individuals with this condition.\n[33]\n\nThe risk of aortic aneurysm and dissection is higher in the 2 months following fluoroquinolone use, especially among older individuals. The underlying cause for this heightened risk remains uncertain. In cases where patients have a confirmed aortic aneurysm or are at an elevated risk for such conditions, it is recommended to consider moxifloxacin as a treatment option only when no alternative antibacterial treatments are feasible.\n[34]",
    "mechanism": "Moxifloxacin exerts its pharmacological effect by inhibiting bacterial DNA synthesis and replication. Moxifloxacin specifically targets 2 crucial enzymes involved in the bacterial DNA replication process—DNA gyrase and topoisomerase IV. By binding to these enzymes, moxifloxacin prevents their ability to unwind and repair DNA strands, resulting in DNA damage and the inhibition of bacterial growth. This mechanism disrupts the bacteria's capacity to reproduce and survive, rendering moxifloxacin effective against a wide range of bacterial infections.\n[6]\n\nRespiratory fluoroquinolones, such as moxifloxacin and levofloxacin, exhibit effectiveness against pivotal causative pathogens, including\nS pneumonia, M pneumoniae, Chlamydia pneumoniae, Legionella pneumophila,\nand various other organisms. Due to their broad-spectrum activity and proven efficacy, these drugs are frequently utilized as standalone therapies for CAP. These drugs are classified as respiratory fluoroquinolones due to their unique chemical structure and potent affinity for targeting pathogens commonly found in respiratory tract infections.\n[7]\n[8]\n\nPharmacokinetics\n\nAbsorption:\nMoxifloxacin can be administered with or without food, and following oral administration, moxifloxacin is absorbed well in the body, displaying an estimated bioavailability of around 90%.\n\nDistribution:\nWith a substantial volume of distribution, moxifloxacin effectively permeates diverse tissues, encompassing the lungs, skin, and prostate. In addition, the drug exhibits favorable penetration into the cerebrospinal fluid.\n\nMetabolism:\nMoxifloxacin undergoes minimal hepatic metabolism, primarily through glucuronidation, and produces inactive metabolites. Notably, the metabolism of moxifloxacin is minimally influenced by cytochrome P450 enzymes.\n\nElimination:\nThe predominant route of elimination for moxifloxacin and its metabolites is through unchanged excretion in the urine. Approximately 45% to 48% of the administered dose is excreted in the urine, primarily in its unchanged form, whereas the remaining portion is eliminated through feces.\n\nThe half-life of moxifloxacin is approximately 12 hours, supporting once-daily dosing in most clinical scenarios. The pharmacokinetics of moxifloxacin exhibit consistency across diverse populations, with no significant differences between genders or age groups. However, dosage adjustments may be necessary in patients with impaired renal function to account for reduced drug clearance.\n[9]\n[10]",
    "administration": "Available Dosage Forms and Strengths\n\nMoxifloxacin is typically administered orally and is available in tablet or oral suspension formulations, facilitating systemic absorption through the digestive tract. In healthcare settings, intravenous (IV) administration is also an option, particularly for more severe infections or situations where oral administration is not feasible. Moxifloxacin is generally not administered rectally, topically, epidurally, intracerebrally, or through enteral routes. The primary modes of delivery for the drug are oral and IV, facilitating systemic distribution and targeting a broad spectrum of infections throughout the body. Localized topical preparations of moxifloxacin may be available for specific eye or ear infections, but these formulations are not administered via routes such as rectal, epidural, or intracerebral means.\n[11]\n[12]\n\nMoxifloxacin tablets are offered in strengths of 400 mg and 600 mg. The oral suspension, with a strength of 400 mg/5 mL, is commonly used in pediatric cases or situations where swallowing tablets poses a challenge. Moxifloxacin IV solutions are available in strengths of 400 mg/250 mL, and they are utilized in hospitals and healthcare settings, particularly for more severe infections or instances where oral medications cannot be administered.\n[13]\n[14]\n\nAdult Dosage\n\nThe recommended adult dosage of moxifloxacin for respiratory tract infections such as pneumonia and bronchitis, skin and soft tissue infections, intra-abdominal infections, acute bacterial sinusitis, and COPD exacerbations is typically 400 mg. Notably, the standard dosage of moxifloxacin is generally 400 mg once daily. The duration of pharmacotherapy varies based on the type and severity of the infection.\n[15]\n[16]\nAccording to FDA-approved product labeling for CAP, a regimen of 7 to 14 days is advised. For uncomplicated skin and skin structure infections, a 7-day course of moxifloxacin is advised. Treatment should extend from 7 to 21 days for cases of complicated skin and skin structure infection.\n\nComplicated intra-abdominal infections necessitate a 5- to 14-day course, while plague requires a 10- to 14-day treatment. For acute bacterial exacerbation of chronic bronchitis, a 5-day course is recommended. Acute bacterial sinusitis necessitates 10 days of treatment. In clinical studies involving individuals with CAP, acute sinusitis, or acute exacerbations of chronic bronchitis (AECB), moxifloxacin administered at a daily dose of 400 mg demonstrated success rates, either in terms of bacteriological or clinical improvement, reaching approximately 90% or greater success.\n[1]\n\nMoxifloxacin exhibited equivalent efficacy to amoxicillin 1 g thrice daily and clarithromycin 500 mg twice daily for the treatment of CAP. Moreover, in AECB, moxifloxacin demonstrated comparable effectiveness to clarithromycin. In patients with sinusitis, a 7-day regimen of moxifloxacin at 400 mg once daily proved equally effective compared to a 10-day course of cefuroxime at 250 mg twice daily.\n[2]\n\nSpecific Patient Populations\n\nHepatic impairment:\nPatients with mild-to-moderate hepatic impairment generally do not necessitate a significant dosage adjustment of moxifloxacin. However, in cases of severe hepatic impairment, a dosage reduction is recommended. Routine monitoring of liver function tests, including serum transaminases—alanine transaminase (ALT) and aspartate transaminase (AST)—levels, is advised to detect any signs of adverse effects or changes in liver function during moxifloxacin treatment. Although hepatotoxicity associated with moxifloxacin is rare, individuals with preexisting liver conditions may be at a higher risk.\n[17]\n[18]\n\nRenal impairment:\nDosage adjustments of moxifloxacin are essential in patients with renal impairment. The extent of adjustment will be determined by the degree of renal dysfunction, typically assessed through creatinine clearance (CrCl). Patients with renal impairment should undergo regular monitoring of their renal function, including assessments of serum creatinine levels and the calculation of CrCl. In individuals undergoing hemodialysis, it is advisable to administer moxifloxacin after dialysis sessions to ensure adequate drug levels.\n[19]\n\nPregnancy considerations:\nMoxifloxacin use during pregnancy should be evaluated on a case-by-case basis, carefully balancing potential benefits against potential risks to the developing fetus. Animal studies have indicated the potential for moxifloxacin to cause congenital disabilities, particularly during the organogenesis period, which is the first trimester.\n\nBreastfeeding considerations:\nAs moxifloxacin is known to be excreted in breast milk, it poses a potential risk of the infant being exposed to the medication through breastfeeding. Healthcare providers should contemplate alternative antibiotics with a more established safety profile during breastfeeding, particularly for non-life-threatening infections. The potential risk of the infant being exposed to the medication through breastfeeding should be taken into consideration.\n\nHealthcare providers should explore alternative antibiotics with a well-established safety profile during breastfeeding, particularly for non-life-threatening infections. The administration of an eye drop containing moxifloxacin by a lactating mother carries minimal risk to the nursing infant. To significantly reduce the transfer of the drug into breast milk after the application of eye drops, gentle pressure should be applied to the tear duct near the eye's corner for 1 minute or more. Any excess solution should be removed using an absorbent tissue.\n[20]\n[21]\n\nPediatric patients:\nThe systemic use of moxifloxacin is not approved by the FDA for pediatric use. Moreover, preclinical studies have indicated that moxifloxacin can induce arthropathy in juvenile animals. However, the efficacy and safety of moxifloxacin ophthalmic solution have been established across all age groups. Clinical studies in adults, children, and neonates provide robust evidence supporting the use of moxifloxacin. Notably, the ophthalmic administration of moxifloxacin ophthalmic solution does not have any impact on weight-bearing joints, unlike certain orally administered quinolones. This is significant because the oral intake of some quinolones has been associated with arthropathy in immature animals.\n\nOlder patients:\nOlder patients, particularly those on corticosteroids, are at an increased risk of severe tendon disorders, including rupture, when treated with fluoroquinolones such as moxifloxacin. In addition, there is an elevated incidence of aortic aneurysm and dissection within 2 months after fluoroquinolone use in older patients. As moxifloxacin injection contains sodium, caution should be exercised in patients with congestive heart failure. Although clinical trials indicate no significant difference in safety and efficacy for oral moxifloxacin in patients 65 or older, caution is still warranted. Older patients may be more susceptible to drug-induced QT interval prolongation, so prudent use is advised, and concurrent administration with QT-prolonging drugs should be avoided.",
    "adverse_effects": "Moxifloxacin is associated with various adverse effects and can result in severe injuries in some cases. The common adverse drug reactions include gastrointestinal symptoms such as nausea, abdominal pain, vomiting, and diarrhea. Patients may experience headaches, dizziness, and, in rare cases, more severe central nervous system (CNS) effects such as confusion or hallucinations. A significant and potentially severe adverse effect of moxifloxacin is the increased risk of tendonitis and tendon rupture, especially in older adults and those concurrently using corticosteroids. Reports indicate that moxifloxacin can lead to changes in heart rhythm (QTc interval prolongation) and an elevated risk of arrhythmias, especially in patients with preexisting heart conditions. Some patients may experience skin rashes, itching, lips, face, and throat swelling due to an allergic reaction to moxifloxacin. Severe allergic reactions such as anaphylaxis are rare but possible. Moxifloxacin has been associated with increased photosensitivity, potentially resulting in heightened susceptibility to sunburn. According to the reports, there are indications of musculoskeletal pain and joint discomfort.\n[22]\n[23]\n\nNotably, although most individuals tolerate moxifloxacin well with few or no adverse effects, these potential adverse effects should be considered, particularly when evaluating the risk-benefit profile for prescribing this medication. Patients should be educated about these possible reactions, and if they experience any concerning symptoms, they should seek medical attention promptly. Moxifloxacin should be used carefully and reserved for situations where other antibiotics are unsuitable, considering its potential for adverse effects. Patients with preexisting comorbidities or those taking medications such as QT-prolonging drugs may face an elevated risk of experiencing these adverse effects. Thus, close monitoring is essential when these individuals are prescribed moxifloxacin.\n[24]\n[25]\n\nDrug-Drug Interactions\n\nConcurrent use of moxifloxacin with antacids, sucralfate, or multivitamins containing aluminum, magnesium, iron, or zinc can reduce the absorption of the drug. Therefore, it is advisable to administer moxifloxacin at least 4 hours before or 8 hours after taking these products. Combining moxifloxacin with other quinolone antibiotics should be avoided due to an increased risk of adverse effects.\n[26]\nCertain nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, may increase the risk of adverse effects on the CNS when taken with moxifloxacin. Therefore, caution is advised when combining these medications. Simultaneously using corticosteroids, such as prednisone, with moxifloxacin may increase the risk of tendonitis and tendon rupture, so concurrent use should be avoided if possible.\n\nMoxifloxacin may increase the anticoagulant effect of drugs such as warfarin, potentially leading to an increased risk of bleeding. Close monitoring of blood clotting parameters may be necessary when these drugs are used together. Combining moxifloxacin with certain antiarrhythmic drugs, such as quinidine, procainamide, amiodarone, and sotalol, can increase the risk of QT interval prolongation and potentially lead to life-threatening cardiac arrhythmias.\n[27]\nThis combination should be avoided or used cautiously under close medical supervision.\n\nMoxifloxacin can increase serum levels of theophylline, necessitating adjustments in theophylline dosage when taken concomitantly. Reports suggest an increased risk of CNS stimulation and seizures when moxifloxacin is used concurrently with selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and paroxetine. Therefore, caution is advised, and close monitoring is recommended if both are used together. As combining moxifloxacin with duloxetine—a medication used to treat depression and anxiety—may increase the risk of serotonin syndrome, careful monitoring is needed if these drugs are taken together. Furthermore, when taken with insulin or oral hypoglycemic agents, moxifloxacin may affect blood glucose levels, potentially leading to hypo- or hyperglycemia. Thus, regular blood glucose monitoring and dosage adjustments may be necessary.\n[28]",
    "monitoring": "The therapeutic index (TI) serves as an indicator of a drug's safety profile, and is calculated by comparing the dose required to induce toxicity in 50% of a population (TD50) with the dosage that yields therapeutic effects in 50% of the population (ED50). This ratio provides valuable insights into the drug's margin of safety. The high therapeutic index of moxifloxacin implies that the effective therapeutic dose is significantly lower than the potentially toxic dose. This underscores a broad margin of safety for therapeutic applications. Moxifloxacin is generally well-tolerated at standard therapeutic doses, with adverse drug reactions becoming more prominent and severe at higher doses.\n[35]\n\nCommon adverse effects at higher doses include gastrointestinal effects such as nausea, vomiting, diarrhea, and abdominal pain, central nervous system effects such as headache, dizziness, and confusion, musculoskeletal effects such as tendonitis or tendon rupture, particularly in older patients and those taking corticosteroids, and cardiovascular effects such as QT interval prolongation, which can lead to arrhythmias. Certain severe adverse effects of moxifloxacin include tendon rupture (tendinitis and tendon rupture, commonly affecting the Achilles tendon but potentially affecting other tendons), phototoxicity (increased sensitivity to sunlight leading to sunburn-like reactions), cardiovascular effects (QTc prolongation associated with potentially life-threatening arrhythmias), and allergic reactions (skin rash, itching, and swelling), which can occur at any dose.\n[36]",
    "toxicity": "Currently, no specific antidote is available for moxifloxacin overdose. Therefore, treatment focuses primarily on symptom management and essential supportive care, including airway maintenance, oxygen supplementation, and hemodynamic support. Gastric lavage or activated charcoal may be considered to limit further drug absorption, depending on the patient's level of consciousness. If the patient is alert and capable of protecting their airway, gastric lavage or activated charcoal can be used to prevent systemic absorption.\n[22]"
  }
}